Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 73 to 79 of 79 entries
Sorted by: Best Match Show Resources per page
Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease.

Physiological reports

Macarlupu JL, Marchant D, Jeton F, Villafuerte F, Richalet JP, Voituron N.
PMID: 33904648
Physiol Rep. 2021 Apr;9(7):e14750. doi: 10.14814/phy2.14750.

Physical exercise may improve hematological conditions in high altitude dwellers suffering from Chronic Mountain Sickness (CMS), in reducing hemoglobin concentration. Therefore, the present study aimed to characterize the effects of 1-month exercise training session in a model of rats...

Cite
Macarlupu JL, Marchant D, Jeton F, et al. Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease. Physiol Rep. 2021;9(7):e14750doi: 10.14814/phy2.14750.
Macarlupu, J. L., Marchant, D., Jeton, F., Villafuerte, F., Richalet, J. P., & Voituron, N. (2021). Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease. Physiological reports, 9(7), e14750. https://doi.org/10.14814/phy2.14750
Macarlupu, José-Luis, et al. "Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease." Physiological reports vol. 9,7 (2021): e14750. doi: https://doi.org/10.14814/phy2.14750
Macarlupu JL, Marchant D, Jeton F, Villafuerte F, Richalet JP, Voituron N. Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease. Physiol Rep. 2021 Apr;9(7):e14750. doi: 10.14814/phy2.14750. PMID: 33904648; PMCID: PMC8077116.
Copy Download .nbib Format: NLM
Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness.

Experimental physiology

Macarlupú JL, Vizcardo-Galindo G, Figueroa-Mujíca R, Voituron N, Richalet JP, Villafuerte FC.
PMID: 34555237
Exp Physiol. 2021 Nov;106(11):2198-2209. doi: 10.1113/EP089975. Epub 2021 Sep 30.

NEW FINDINGS: What is the central question of this study? What is the effect of sub-maximal aerobic exercise training on signs and symptoms of chronic mountain sickness (CMS) in Andean highlanders? What is the main finding and its importance?...

Cite
Macarlupú JL, Vizcardo-Galindo G, Figueroa-Mujíca R, et al. Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness. Exp Physiol. 2021;106(11):2198-2209doi: 10.1113/EP089975.
Macarlupú, J. L., Vizcardo-Galindo, G., Figueroa-Mujíca, R., Voituron, N., Richalet, J. P., & Villafuerte, F. C. (2021). Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness. Experimental physiology, 106(11), 2198-2209. https://doi.org/10.1113/EP089975
Macarlupú, José Luis, et al. "Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness." Experimental physiology vol. 106,11 (2021): 2198-2209. doi: https://doi.org/10.1113/EP089975
Macarlupú JL, Vizcardo-Galindo G, Figueroa-Mujíca R, Voituron N, Richalet JP, Villafuerte FC. Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness. Exp Physiol. 2021 Nov;106(11):2198-2209. doi: 10.1113/EP089975. Epub 2021 Sep 30. PMID: 34555237.
Copy Download .nbib Format: NLM
Accuracy and Reliability of Pulse O2 Saturation Measured by a Wrist-worn Oximeter.

International journal of sports medicine

Hermand E, Coll C, Richalet JP, Lhuissier FJ.
PMID: 34000752
Int J Sports Med. 2021 May 17; doi: 10.1055/a-1337-2790. Epub 2021 May 17.

This study aims to evaluate the accuracy of the Garmin Forerunner 245 heart rate (HR) and pulse O

Cite
Hermand E, Coll C, Richalet JP, et al. Accuracy and Reliability of Pulse O2 Saturation Measured by a Wrist-worn Oximeter. Int J Sports Med. 2021;doi: 10.1055/a-1337-2790.
Hermand, E., Coll, C., Richalet, J. P., & Lhuissier, F. J. (2021). Accuracy and Reliability of Pulse O2 Saturation Measured by a Wrist-worn Oximeter. International journal of sports medicine, . https://doi.org/10.1055/a-1337-2790
Hermand, Eric, et al. "Accuracy and Reliability of Pulse O2 Saturation Measured by a Wrist-worn Oximeter." International journal of sports medicine vol. (2021). doi: https://doi.org/10.1055/a-1337-2790
Hermand E, Coll C, Richalet JP, Lhuissier FJ. Accuracy and Reliability of Pulse O2 Saturation Measured by a Wrist-worn Oximeter. Int J Sports Med. 2021 May 17; doi: 10.1055/a-1337-2790. Epub 2021 May 17. PMID: 34000752.
Copy Download .nbib Format: NLM
The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase.

Bioorganic chemistry

Pereira MS, de Araújo SS, Nagem RAP, Richard JP, Brandão TAS.
PMID: 34965488
Bioorg Chem. 2021 Dec 16;119:105561. doi: 10.1016/j.bioorg.2021.105561. Epub 2021 Dec 16.

Salicylate hydroxylase (NahG) has a single redox site in which FAD is reduced by NADH, the O

Cite
Pereira MS, de Araújo SS, Nagem RAP, et al. The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase. Bioorg Chem. 2021;119:105561doi: 10.1016/j.bioorg.2021.105561.
Pereira, M. S., de Araújo, S. S., Nagem, R. A. P., Richard, J. P., & Brandão, T. A. S. (2021). The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase. Bioorganic chemistry, 119105561. https://doi.org/10.1016/j.bioorg.2021.105561
Pereira, Mozart S, et al. "The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase." Bioorganic chemistry vol. 119 (2021): 105561. doi: https://doi.org/10.1016/j.bioorg.2021.105561
Pereira MS, de Araújo SS, Nagem RAP, Richard JP, Brandão TAS. The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase. Bioorg Chem. 2021 Dec 16;119:105561. doi: 10.1016/j.bioorg.2021.105561. Epub 2021 Dec 16. PMID: 34965488.
Copy Download .nbib Format: NLM
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

NPJ breast cancer

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S.
PMID: 34853355
NPJ Breast Cancer. 2021 Dec 01;7(1):150. doi: 10.1038/s41523-021-00346-1.

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients...

Cite
El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150doi: 10.1038/s41523-021-00346-1.
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S. W., Lien, H. C., Kirtani, P., Balancin, M., El Attar, H., Guleria, P., Yang, W., Shash, E., Chen, I. C., Bautista, V., Do Prado Moura, J. F., Rapoport, B. L., Castaneda, C., Spengler, E., Acosta-Haab, G., Frahm, I., Sanchez, J., Castillo, M., Bouchmaa, N., Md Zin, R. R., Shui, R., Onyuma, T., Yang, W., Husain, Z., Willard-Gallo, K., Coosemans, A., Perez, E. A., Provenzano, E., Ericsson, P. G., Richardet, E., Mehrotra, R., Sarancone, S., Ehinger, A., Rimm, D. L., Bartlett, J. M. S., Viale, G., Denkert, C., Hida, A. I., Sotiriou, C., Loibl, S., Hewitt, S. M., Badve, S., Symmans, W. F., Kim, R. S., Pruneri, G., Goel, S., Francis, P. A., Inurrigarro, G., Yamaguchi, R., Garcia-Rivello, H., Horlings, H., Afqir, S., Salgado, R., Adams, S., Kok, M., Dieci, M. V., Michiels, S., Demaria, S., Loi, S. (2021). The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ breast cancer, 7(1), 150. https://doi.org/10.1038/s41523-021-00346-1
El Bairi, Khalid, et al. "The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group." NPJ breast cancer vol. 7,1 (2021): 150. doi: https://doi.org/10.1038/s41523-021-00346-1
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 01;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355; PMCID: PMC8636568.
Copy Download .nbib Format: NLM
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.

Oncotarget

Kulkarni A, McDermott JR, Kathad U, Modali R, Richard JP, Sharma P, Bhatia K.
PMID: 33889302
Oncotarget. 2021 Apr 13;12(8):791-806. doi: 10.18632/oncotarget.27943. eCollection 2021 Apr 13.

More than 40% of non-small cell lung cancer (NSCLC) patients lack actionable targets and require non-targeted chemotherapeutics. Many become refractory to drugs due to underlying resistance-associated mutations. KEAP1 mutant NSCLCs further activate NRF2 and upregulate its client PTGR1. LP-184,...

Cite
Kulkarni A, McDermott JR, Kathad U, et al. The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations. Oncotarget. 2021;12(8):791-806doi: 10.18632/oncotarget.27943.
Kulkarni, A., McDermott, J. R., Kathad, U., Modali, R., Richard, J. P., Sharma, P., & Bhatia, K. (2021). The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations. Oncotarget, 12(8), 791-806. https://doi.org/10.18632/oncotarget.27943
Kulkarni, Aditya, et al. "The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations." Oncotarget vol. 12,8 (2021): 791-806. doi: https://doi.org/10.18632/oncotarget.27943
Kulkarni A, McDermott JR, Kathad U, Modali R, Richard JP, Sharma P, Bhatia K. The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations. Oncotarget. 2021 Apr 13;12(8):791-806. doi: 10.18632/oncotarget.27943. eCollection 2021 Apr 13. PMID: 33889302; PMCID: PMC8057270.
Copy Download .nbib Format: NLM
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.

Molecular neurodegeneration

Li Q, Feng Y, Xue Y, Zhan X, Fu Y, Gui G, Zhou W, Richard JP, Taga A, Li P, Mao X, Maragakis NJ, Ying M.
PMID: 35012575
Mol Neurodegener. 2022 Jan 10;17(1):8. doi: 10.1186/s13024-021-00510-y.

BACKGROUND: Spinal cord motor neurons (MNs) from human iPS cells (iPSCs) have wide applications in disease modeling and therapeutic development for amyotrophic lateral sclerosis (ALS) and other MN-associated neurodegenerative diseases. We need highly efficient MN differentiation strategies for generating...

Cite
Li Q, Feng Y, Xue Y, et al. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Mol Neurodegener. 2022;17(1):8doi: 10.1186/s13024-021-00510-y.
Li, Q., Feng, Y., Xue, Y., Zhan, X., Fu, Y., Gui, G., Zhou, W., Richard, J. P., Taga, A., Li, P., Mao, X., Maragakis, N. J., & Ying, M. (2022). Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Molecular neurodegeneration, 17(1), 8. https://doi.org/10.1186/s13024-021-00510-y
Li, Qian, et al. "Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells." Molecular neurodegeneration vol. 17,1 (2022): 8. doi: https://doi.org/10.1186/s13024-021-00510-y
Li Q, Feng Y, Xue Y, Zhan X, Fu Y, Gui G, Zhou W, Richard JP, Taga A, Li P, Mao X, Maragakis NJ, Ying M. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Mol Neurodegener. 2022 Jan 10;17(1):8. doi: 10.1186/s13024-021-00510-y. PMID: 35012575; PMCID: PMC8751314.
Copy Download .nbib Format: NLM
Showing 73 to 79 of 79 entries